Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade plus Vorinostat in High Risk MDS and Relapsed/Refractory AML
NCT00818649Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2009
- Primary completion
- May 2012
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, vorinostat in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Jan 2009; status: terminated.
02
Drugs
bortezomibvorinostat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00818649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00818649.